Ticagrelor in patients with myocardial infarction: is the treatment strategy crystal clear?

Affiliations

¹ University of Western Australia, School of Medicine and Pharmacology-Royal Perth Hospital Unit, Perth, Western Australia.
² Heart Diseases Institute, Hospital Universitario de Bellvitge - IDIBELL, CIBER-CV; L'Hospitalet de Llobregat, Barcelona, Spain.

Comment

Leslie Marisol Lugo et al. Eur Heart J Cardiovasc Pharmacother. 2019.

. 2019 Oct 1;5(4):207-209.

doi: 10.1093/ehjcvp/pvz023.

¹ University of Western Australia, School of Medicine and Pharmacology-Royal Perth Hospital Unit, Perth, Western Australia.
² Heart Diseases Institute, Hospital Universitario de Bellvitge - IDIBELL, CIBER-CV; L'Hospitalet de Llobregat, Barcelona, Spain.

No abstract available

Comment on

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.
Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Oude Ophuis T, Budaj A, Hamm C, Spinar J, Kiss RG, Lopez-Sendon J, Kamensky G, Van de Werf F, Ardissino D, Kontny F, Montalescot G, Johanson P, Bengtsson O, Himmelmann A, Braunwald E, Sabatine MS. Dellborg M, et al. Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):200-206. doi: 10.1093/ehjcvp/pvz020. Eur Heart J Cardiovasc Pharmacother. 2019. PMID: 31218354 Free PMC article.